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Background: This study evaluates the potential utility of a modular nanotransporter (MNT) for enhancing the
nuclear delivery and cytotoxicity of the Auger electron emitter 125I in cancer cells that overexpress the epidermal
growth factor receptor (EGFR).
Methods: MNTs are recombinant multifunctional polypeptides that we have developed for achieving selective
delivery of short-range therapeutics into cancer cells. MNTs contain functional modules for receptor binding,
internalization, endosomal escape and nuclear translocation, thereby facilitating the transport of drugs from the cell
surface to the nucleus. The MNT described herein utilized EGF as the targeting ligand and was labeled with 125I
using N-succinimidyl-4-guanidinomethyl-3-[125I]iodobenzoate (SGMIB). Membrane binding, intracellular and nuclear
accumulation kinetics, and clonogenic survival assays were performed using the EGFR-expressing A431 epidermoid
carcinoma and D247 MG glioma cell lines.
Results: [125I]SGMIB-MNT bound to A431 and D247 MG cells with an affinity comparable to that of native EGF.
More than 60% of internalized [125I]SGMIB-MNT radioactivity accumulated in the cell nuclei after a 1-h incubation.
The cytotoxic effectiveness of [125I]SGMIB-MNT compared with 125I-labeled bovine serum albumin control was
enhanced by a factor of 60 for D247 MG cells and more than 1,000-fold for A431 cells, which express higher levels
of EGFR.
Conclusions: MNT can be utilized to deliver 125I into the nuclei of cancer cells overexpressing EGFR, significantly
enhancing cytotoxicity. Further evaluation of [125I]SGMIB-MNT as a targeted radiotherapeutic for EGFR-expressing
cancer cells appears warranted.
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Radionuclides emitting densely ionizing Auger electrons
impart high cytotoxicity when they decay in close proxim-
ity to nuclear DNA due to the formation of double-strand
breaks, resulting in severe DNA damage [1]. Because
Auger electrons are characterized by short path lengths
in the tissue and a very high linear energy transfer, their
cytotoxic effects are limited to a sphere of a few* Correspondence: sobolev@igb.ac.ru
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in any medium, provided the original work is pnanometers in the immediate vicinity of the site of decay
[2]. This property potentially makes them highly selective
for killing targeted single cancer cells, provided that they
can be specifically delivered to tumor cells, internalized,
and transported to the cell nucleus [3].
For achieving selective delivery of short-range, highly
cytotoxic therapeutics to their intended target cell
populations, we have created engineered recombinant
molecules - modular nanotransporters (MNT) - consisting
of domains for accomplishing receptor binding and in-
ternalization as well as endosomal escape and nuclear
translocation, thereby facilitating the delivery of drugs
from the cell surface to the nucleus. We have recentlys is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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short range-of-action photosensitizers in vitro [4,5] and
in vivo [6] with high cytotoxic effectiveness. Moreover,
we have demonstrated proof of principle for using
MNT as a platform for developing targeted short-range
(α-particle) radiotherapeutic agents for cancer therapy
[7]. Based on these encouraging results, we hypothesized
that MNT might also be a useful vehicle for exploiting
the high potency and subcellular range of Auger elec-
trons for targeted radiotherapy, enabling specific delivery
of Auger electron-emitting radionuclides to the highly
radiosensitive cell nucleus of cancer cells.
A promising advantage of MNT is the interchangeable
nature of the modules, offering the exciting prospect of
generating an MNT or an MNT cocktail that possesses
the best ligand, or mixture of ligands, and intracellular
localizing signals that are tailored to the molecular pro-
file of an individual patient’s tumor. The present study
focuses on the development and the in vitro evaluation
of a radiolabeled MNT possessing epidermal growth fac-
tor (EGF) as the ligand module, which ultimately might
be suitable for targeting the many types of cancers
overexpressing EGF receptors (EGFR) [8]. Iodine-125
was selected for these studies because it is the most
well-studied Auger electron emitter 125I for targeted
radiotherapy [9]. Although some of the properties of
125I (60-day half life, labeling chemistry) can present
obstacles for eventual clinical translation, this radio-
nuclide was selected to evaluate the feasibility of MNT
mediated delivery of Auger electron emitters for several
reasons. First, 125I is the most prototypic and well-
studied Auger electron emitter for targeted radiotherapy
[9]. And second, the fraction of total decay energy repre-
sented by Auger electron emission for 125I is higher than
that for most alternative Auger electron emitters, in-
cluding 123I, 67Ga, and 111In [1], making subcellular site
of decay highly relevant. Binding, internalization, nuclear
translocation and cytotoxicity were evaluated using two
EGFR-expressing human cancer cell lines - A431 epi-
dermoid carcinoma cells and D247 MG malignant glioma
cells, which express varying levels of EGFR.
Methods
Cell lines
The human epidermoid carcinoma cell line A431 [10]
was obtained from the ATCC (Manassas, VA, USA), and
the human glioblastoma cell line D247 MG [11] was
kindly provided by Dr. Darell Bigner, Duke University
Medical Center. Previous studies in our laboratory indi-
cated that the average number of EGFR per cell is
2.9 × 106 and 2.4 × 105 for A431 and D247 MG cells,
respectively [7]. All tissue culture reagents were obtained
from Gibco/Invitrogen (Carlsbad, CA, USA). The cells
were cultured in zinc option medium supplemented with10% fetal bovine serum and penicillin/streptomycin
(100 U/mL) at 37°C in a 5% CO2 atmosphere.
Modular nanotransporter
The MNT molecule used in these experiments was
DTox-HMP-NLS-EGF (hereafter designated as MNT),
which has a molecular weight of 76.3 kDa. DTox is the
translocation domain of diphtheria toxin, serving as the
endosomolytic module; HMP is an Escherichia coli
hemoglobin-like protein, serving as the carrier module;
the NLS is the optimized simian vacuolating virus
40 (SV40) large T-antigen nuclear localization sequence
peptide; and EGF served as the ligand module [5]. The
MNT was purified to >98% purity on Ni-NTA-agarose
(QIAGEN, Hilden, Germany) according to the standard
procedure furnished by the supplier. Each MNT module
retained its intended function: high affinity interaction
with EGFR and α/β-importin dimers, ensuring nuclear
transport of NLS-containing protein, formation of holes
in lipid bilayers at endosomal pH, and accumulation in
the nuclei of A431 cells [5].
Labeling MNT and EGF with 125I using N-succinimidyl-4-
guanidinomethyl-3-[125I]iodobenzoate
No-carrier-added sodium [125I]iodide (2,200 Ci/mmol)
was obtained from Perkin-Elmer Life and Analytical
Sciences (Boston, MA, USA). A detailed method for the
radiosynthesis of N-succinimidyl-4-guanidinomethyl-
3-[125I]iodobenzoate (SGMIB) and its use for labeling in-
ternalizing molecules have been described in a previous
publication [12]. Briefly, a solution of the MNT (50 μL,
2 mg/mL), or human EGF (hEGF) (Sigma Chemical,
St. Louis, MO, USA; 50 μL, 1 mg/mL) in 0.1 M borate
buffer (pH 8.5) was added to [125I]SGMIB, and the
mixture was incubated at room temperature for 20 min.
The radiolabeled polypeptide conjugate was purified by
gel filtration through a PD-10 column (GE Healthcare,
Pittsburgh, PA, USA) that was eluted with phosphate-
buffered saline (pH 7.5).
Labeling with 125I using Iodogen
For radioligand assays, hEGF and bovine serum albu-
min (BSA) (Sigma Chemical, St. Louis, MO, USA)
were labeled with 125I using Iodogen (Pierce, Rockford,
IL, USA). The proteins and 1 to 3 mCi of sodium
[125I]iodide in phosphate-buffered saline (pH 7.5)
were incubated in glass vials coated with 10 μg of
Iodogen for 15 min. Radioiodinated proteins were
purified by passage through a PD-10 column as
described above.
Binding assays
The EGFR status of the two cell lines was confirmed by
measuring [125I]iodoEGF binding, and the ability of
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EGFR was documented as previously described [7] prior
to the initiation of any of the other experiments.Uptake and washout kinetics
The uptake and washout kinetics of [125I]SGMIB-MNT
were measured on A431 and D247 MG cells in order to
relate the cytotoxic effect to the number of 125I disinte-
grations. Cells were seeded in 24-well plates (5 × 104 cells
per well). Two days later, the cells were washed, and
[125I]SGMIB-MNT (specific activity 12.8 mCi/mg) in
media was added at a final concentration of 2.6 nM.
The cells were incubated in triplicate for 0.5, 1, 2, 4, 8,
12, and 24 h in a humidified atmosphere at 37°C in
5% CO2. At each time point, an aliquot of media con-
taining unbound radioactivity was collected, and the
cells were washed with ice-cold Dulbecco's phosphate-
buffered saline (DPBS) without calcium and magnesium.
The cells were trypsinized and harvested for centrifuga-
tion. The membrane-bound radioactivity [13-15] released
into the supernatant was collected, and the cells were
resuspended in medium and centrifuged once more.
The supernatant samples were collected along with the
previous washes, while the pelleted cells were resus-
pended in medium. The internalized radioactivity from
the resuspended cells, as well as the free radioactivity
and the membrane-bound radioactivity samples, were
counted for 125I activity using an automated gamma
counter (Wallac Wizard 3”; Perkin-Elmer Life and Ana-
lytical Sciences, IL, USA). To determine washout kin-
etics, the cells were incubated with 0.3 nM of [125I]
SGMIB-MNT (specific activity 6.0 mCi/mg) for 24 h at
37°C. After trypsinization and washing, the cells were
resuspended in media and incubated for 0.5, 2, 4, 8, and
24 h at 37°C in 5% CO2. The washed out radioactivity
was removed by centrifugation, followed by an additional
washing of the cells with medium, and centrifuged again.
After counting the 125I activity, the results were calcu-
lated as counts per minute per cell (CPM/cell) of interna-
lized radioactivity as a function of time.Nuclear kinetics in A431 cells
The protocol for isolation of cell nuclei was based on a
widely used method [16]. In brief, the cells were seeded
in 6-well plates (5 × 105 cells per well); 2 days later,
the cells were washed, and [125I]SGMIB-MNT (specific
activity 1.3 to 2.1 mCi/mg for these experiments) was
added at a concentration (30 to 43 nM) selected based
on the measured Kd. Cells were incubated in triplicate
for 1, 2, 4, 8, and 24 h at 37°C in 5% CO2. For the deter-
mination of nonspecific uptake, EGF in 100-fold excess
also was added to the cells. At each time point, mediumcontaining unbound radioactivity was collected, and the
cells were washed three times with 1 ml of ice-cold DPBS
without calcium and magnesium. The cells were trypsi-
nized and harvested for centrifugation. The pelleted cells
were resuspended in 0.5-mL ice-cold medium and centri-
fuged for a second time. The membrane-bound radio-
activity released in these two supernatants was collected.
The cells were swelled for 20 min on ice in 500 μL
of ice-cold hypotonic buffer (25 mM Tris–HCl pH 7.5,
5 mM KCl, 0.5 mM dithiothreitol, 1 mM phenylmetha-
nesulfonylfluoride, and 0.15 U/mL aprotinin), and 50 μL
were removed for counting intracellular radioactivity.
Following homogenization using a Dounce homogenizer
on ice, the nuclei were pelleted by centrifugation at
600 × g for 10 min. Pelleted nuclei were washed three
times with isotonic buffer (0.25 M sucrose, 6 mM MgCl2,
10 mM Tris–HCl, pH 7.4, 0.5% Triton X-100, 1 mM
phenylmethanesulfonylfluoride, and 0.15 U/mL aprotinin)
to remove any contamination from cytoplasmic mem-
branes. The purity of the nuclear fraction was confirmed
by careful microscopic evaluation and Western Blot
analysis using antibodies to α-tubulin and histone deace-
tylase 1 (HDAC-1) as cytoplasmic and nuclear markers,
respectively.
Cytotoxicity study
Briefly, A431 or D247 MG cells were seeded in 24-well
plates (5 × 104 cells per well) and 2 days later were
washed with media. A range of radioactive concentra-
tions of [125I]SGMIB-MNT (0 to 101 μCi/mL), [125I]
SGMIB-EGF (0 to 41 μCi/mL, only with A431 cells) or
as a negative control, 125I-labeled bovine serum albumin
([125I]iodoBSA) (0 to 454 μCi/mL), were added, and the
cells were incubated for 24 h in a humidified atmosphere
at 37°C in 5% CO2. After the incubation, medium con-
taining unbound radioactivity was removed, and the cells
were washed twice with cold DPBS without calcium and
magnesium. The cells were trypsinized and harvested
prior to centrifugation. The supernatant representing the
membrane-bound radioactivity was collected. The cells
were resuspended in medium, and an aliquot was col-
lected in order to assay the amount of internalized
radioactivity using the automated gamma counter. The
cells were counted, seeded for a colony-forming assay in
25-cm2 flasks (2,000 cells per flask), and maintained in a
humidified atmosphere at 37°C in 5% CO2. After 6 to
7 days (A431 cells) or 11 to 14 days (D247 MG cells),
the colonies were stained with crystal violet and were
counted. The data were analyzed using GraphPad Prism
Version 5.01 software (GraphPad, San Diego, CA, USA).
Survival experiments were performed three separate
times (A431 cells) or twice (D247 MG cells). Each experi-
ment was done in triplicate.
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and nucleus
From the curves obtained for internalized CPM uptake
and washout versus time (determined as described above
in the uptake and washout kinetics section), the total
number of 125I CPM delivered to the cells during the









where cpm1 (t) represents accumulation kinetics function
of [125I]SGMIB-MNT and cpm2 (t) represents the wash-
out kinetics function of [125I]SGMIB-MNT measured for
each cell line. By correction for the detection efficiency
of the gamma counter, the total number of disintegra-
tions per cell was calculated.
The total number of decays accumulated per nucleus
over the incubation was estimated using the following
calculations and assumptions:
1) The area under the curve, expressed as the number
of decays accumulated per nucleus over the
incubation with predefined concentration of [125I]
SGMIB-MNT, was calculated from the nuclear
kinetics experiment data (0 to 24 h).
2) It was assumed that the percentage of decays that
occurred per nucleus is constant over the range of
[125I]SGMIB-MNT concentrations used in
cytotoxicity studies.
Thus, decays occurring per nucleus were calculated for
each concentration used in the cytotoxicity study accord-
ing to the following equation:
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where a is a factor which takes into account both the effi-
ciency of the gamma counter (0.85 for 125I) and the
abundance of its gamma photon used for measurement,
x024 h ¼ decays per nucleustotal decays per cell , accumulated over the 24-h in-
cubation (this is obtained from the nuclear kinetics ex-
periment, x24 h ¼ decays per nucleustotal decays per cell at the end of incubation









 cpm2 tð Þdt were
calculated as described above.
Results and discussion
Results
Labeling and quality control of [125I]SGMIB-MNT
The yield for the MNT conjugation reaction was 60% to
80%, with >97% of the radioactivity protein associated,
as determined by trichloroacetic acid precipitation. The
specific activity of [125I]SGMIB-MNT varied from 1.3 to
12.8 mCi/mg. Gel electrophoresis of [125I]SGMIB-MNT
and subsequent phosphor imaging of the dried gel
showed one main band at about 75 kDa, which is con-
sistent with the molecular weight of MNT (Figure 1a).
The specific binding of [125I]SGMIB-MNT to EGFR-
overexpressing A431 human epidermoid carcinoma and
D247 MG human glioma cells (Figure 1b,d) as a func-
tion of concentration was similar to that observed for
[125I]iodoEGF (Figure 1c,e). The binding affinity of [125I]
SGMIB-MNT (Kd = 20.5 ± 2.6 nM), for EGFR measured
on A431 cells was somewhat lower than that of [125I]
iodoEGF (Kd = 9.5 ± 0.9 nM) but within the error of that
obtained for unmodified MNT (Kd = 21.4 ± 2.6 nM;
obtained from a competitive assay versus [125I]iodoEGF),
suggesting that labeling did not compromise the
MNT binding affinity. The binding affinity of [125I]
SGMIB-MNT (Kd = 0.98 ± 0.64 nM) for EGFR measured
on D247 MG cells was similar to that of [125I]iodoEGF
(Kd = 2.1 ± 0.5 nM).
Binding/uptake and washout kinetics
The kinetics of membrane binding and internalization of
[125I]SGMIB-MNT by A431 and D247 MG cells was
investigated at selected time points up to 24 h. Intracel-
lular and surface-bound radioactivity increased rapidly
during the first 8 h of incubation, reaching near plateau
values at 24 h (Figure 2a,b). Based on these results and
taking into account the 60-day half-life of 125I, a 24-h
incubation period was used for measuring washout
kinetics and for performing the cytotoxicity assays. The
initial washout kinetics of radioactivity from these EGFR-
positive cell lines was rapid; however, approximately 30%
of initially internalized radioactivity was retained inside
the cells at 24 h (Figure 2c,d).
The exponential functions y = ymax(1 − e
−kx) and
y = ymax − e
−kx were fit, respectively, to the experimental
intracellular accumulation and washout kinetics data
(CPM inside the cell versus time curves; Figure 2),
with a good fit (R2 = 0.97) observed for both cell lines.
The coefficients ymax and k were defined with the
GraphPad Prism software from the kinetics data, for
Figure 1 Quality control of [125I]SGMIB-MNT. (a) Phosphor image of the dried SDS-PAGE gel (Any kD™ Mini-PROTEANW TGX™ Precast Gels, Bio-
Rad, CA, USA) of [125I]SGMIB-MNT. The main band at about 75 kD standard band corresponds to full-sized [125I]SGMIB-MNT (57%), while the minor
band at about 150 kD (12%) is consistent with an MNT dimer. (b) [125I]SGMIB-MNT and (c) [125I]iodoEGF binding to A431 cells. (d) [125I]SGMIB-MNT
and (e) [125I]iodoEGF binding to D247 MG cells. Bars represent standard error of mean.
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cient k was set by assuming that the shape of kinetics
functions was independent of [125I]SGMIB-MNT con-
centration (c). We calculated ymax(c) from the experi-
mentally determined intracellular activity levels
measured after a 24-h incubation at each concentration
of [125I]SGMIB-MNT evaluated in the cytotoxicity
experiment. Thus, we obtained cpm1 (t) and cpm2 (t) at
each concentration.Nuclear kinetics
Because of the enhanced cytotoxicity of Auger electrons
when localized in the cell nucleus, the dynamics of 125I
localization in the cell nucleus after incubation of A431
cells with [125I]SGMIB-MNT was determined. The cell
nuclei were isolated using a method previously reported
by Lo et al. [16], which was successfully applied for the
subcellular fractionation of A431 cells. Western blot
analysis revealed negligible contamination of isolated nu-
clei with the abundant cytoplasmic protein, α-tubulin
(Figure 3a), and low contamination of the cytoplasmic
fraction with the soluble nuclear protein HDAC-1
(Figure 3b). The kinetics of nuclear accumulation of
[125I]SGMIB-MNT was fast, with more than 60% of
the total intracellular radioactivity in the nuclei after 1
h (Figure 3c). About 40% (from 0.27 CPM/nucleus at 1
h to 0.16 CPM/nucleus at 4 h) was redistributed fromthe cell nuclei over the next 3 h, gradually reducing to
0.07 CPM/nucleus at the end of the 24-h incubation.Cytotoxicity
The clonogenic survival of EGFR-expressing A431 and
D247 MG cells after a 24-h exposure to varying radio-
activity concentrations of [125I]SGMIB-MNT and [125I]
SGMIB-EGF and as a control for nonspecific cytotox-
icity, [125I]iodoBSA, are presented in Figure 4 and Table 1
([125I]SGMIB-MNT only). For [125I]SGMIB-MNT, the
relationship between clonogenic survival and radio-
activity concentration added to the medium was poorly
fitted by a one-exponential model for both cell lines but
were fitted effectively with two-exponential equations.
The fitted curves were utilized to estimate the added
radioactivity per well required to reduce survival to
37% (A37). The A37 values for [
125I]SGMIB-MNT and
[125I]iodoBSA were 2.7 × 106 DPM (N37 ~ 3,000 decays
per cell, or approximately 320 decays per nucleus) and
approximately 1.5 × 1010 DPM (extrapolated), respect-
ively, for A431 epidermoid carcinoma cells (Figure 4a,
Table 1), and 1.2 × 107 DPM (N37 ~ 3,800 decays per cell)
and 7.6 × 108 DPM, respectively, for D247 MG glioma
cells (Figure 4b, Table 1). These results demonstrate
that the cytotoxic effectiveness of [125I]SGMIB-MNT
was 60 and more than 3,500 higher than that of non-
specific [125I]iodoBSA on the lower EGFR-expressing
Figure 2 [125I]SGMIB-MNT binding/uptake and washout kinetics. Kinetics of binding and accumulation of [125I]SGMIB-MNT by (a) A431
human epidermoid carcinoma cells and (b) D247 MG human glioma cells. Total activity accumulated inside the cells (circles); total membrane-
bound activity (squares). Washout kinetics of intracellular accumulated after 24 h of incubation [125I]SGMIB-MNT by (c) A431 human epidermoid
carcinoma cells and (d) D247 MG human glioma cells. All data are expressed as activity in CPM per cell. For each data point, the experiment was
done in triplicate with bars representing the standard error of mean.
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respectively. The cytotoxic effectiveness of [125I]SGMIB-
MNT was 4.6 (when comparing A37) or 18.3 (when
comparing more sensitive A10 values) times higher than
that of [125I]SGMIB-EGF (Figure 5).
Discussion
Due to the very short range of Auger electrons (0.15 to
22.5 nm in the tissue for 125I [17]), radionuclides that
decay via Auger electron emission need to be delivered
in close proximity to DNA within the nucleus to effi-
ciently kill the target cells. The importance of localizing
the site of decay in the cell nucleus can be illustrated by
comparing the cellular S values (absorbed dose per unit
cumulated activity) for 125I, considering a cell with cell
and nuclear diameters of 18 and 10 μm, respectively, as
an example [18]. In this case, shifting the site of decay
from an extracellular site 1 μm from the cell surface, the
cell membrane or the cytoplasm to the cell nucleus
results in an enhancement of the radiation dose (gray
per bequerel second) of 47, 39, and 21, respectively,
highlighting the necessity of achieving a nuclear site ofdecay in order to maximize the therapeutic potential of
Auger electron-emitting radionuclides. According to
this formalism, the extent of enhancement calculated for
a particular Auger electron emitter is dependent on the
energetics and abundances of its Auger electron spectra
as well as the geometry of the target cell. For some other
Auger electron emitters that have been frequently inves-
tigated for targeted radiotherapy (67Ga, 77Br, 111In, and
123I), shifting the decay site from a cell surface receptor
to the cell nucleus should increase the radiation dose
received by the cell nucleus by at least a factor of 25 [18].
The most widely explored approach for delivering
Auger electron emitters to the cell nucleus utilizes
the thymidine analogue, 5-[125I]iodo-2'-deoxyuridine
(125IUdR), which can be incorporated into the DNA
of cells in S-phase [19]. This strategy attempts to exploit
the more rapid proliferation of malignant compared with
normal cell populations. Although the limitations of
IUdR are recognized, this agent provides an important
point of reference because its effectiveness in vitro
(in decays per cell/nucleus) reflects that achieved with 125I
when nearly all its decays occur in DNA-incorporated
Table 1 Cytotoxicity of [125I]SGMIB-MNT expressed as
decays per cell or per nucleus
Cell line A431 D247 MG
Mean SE (n = 3) Mean SE (n = 2)
A37 (decays per cell) 3,001 624 3,819 878
A37 (decays per nucleus) 317 66 N/D N/D
N/D, not determined.
Figure 3 [125I]SGMIB-MNT nuclear kinetics. Western blot analysis
for (a) α-tubulin (a cytoplasmic protein) and (b) histone deacytalase-1
(nuclear protein) in cytoplasmic fraction or nuclear fraction from A431
cells. (c) Nuclear kinetics of [125I]SGMIB-MNT in A431 cells (circles and
squares refer to separate experiments). For each data point, the
experiment was done in triplicate with bars representing the standard
error of mean.
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cell and decays per cell nucleus for 125IUdR are approxi-
mately the same. For Chinese hamster V79 lung fibro-
blasts, an N37 equal to 120 decays per cell nucleus has
been reported [19] under the same experimental condi-
tions utilized herein for determining the cytotoxicity of
[125I]SGMIB-MNT on A431 cells, where N37 is estimated
to be approximately 320 decays per nucleus.
In a previous study, we measured the cytotoxicity of
125IUdR for D247 MG glioma cells, one of the cell linesFigure 4 Cytotoxicity of [125I]SGMIB-MNT. Clonogenic survival of (a) A43
cells after exposure for 24 h to varying activity concentrations of [125I]SGMI
separate times (A431 cells) or twice (D247 MG cells) with survival curves of
point, the experiment was done in triplicate with bars representing the stautilized in the current study [20]. The A37 determined
after a 20-h incubation was 115 kBq/mL (3.1 μCi/mL).
The cytotoxicity of [125I]SGMIB-MNT (9 μCi/mL) was
somewhat lower than that reported for 125IUdR, both in
terms of activity in the medium and N37, which is con-
sistent with the fact that unlike the case of 125IUdR, 125I
delivered by [125I]SGMIB-MNT would not be expected
to be incorporated into the DNA.
However, it should be noted that cytotoxicity of Auger
electron emitters, like other forms of radiation, can be
influenced by the bystander effect, which is independent
of the subcellular localization site of the radionuclide.
For example, it was recently shown that this important,
yet not fully understood, effect can be evoked by both
nuclear (123/125IUDR) and mostly extra-nuclear ([123I]
MIBG) localized Auger electron emitters, modulating
cytotoxicity of neighbor malignant cells [9,21,22].
Although 125IUdR has a considerable advantage from a
cytotoxicity perspective, it also has significant limitations
as an Auger-emitting targeted radiotherapeutic that have
complicated its application in the clinical domain. These
include an uptake mechanism limited to cells in S-phase,
marginal tumor selectivity, extremely poor in vivo sta-
bility, and lack of suitability for use with radiometals
such as 111In and 67Ga, which have half lives of about
3 days and thus could be more practical alternatives for
clinical use than 60-day half life 125I. This has led a
number of groups to evaluate proteins or peptides that1 human epidermoid carcinoma cells and (b) D247 MG human glioma
B-MNT and [125I]iodoBSA. The experiments were performed three
the representative experiment shown on the graph. For each data
ndard error of mean.














Figure 5 Comparison of [125I]SGMIB-MNT and [125I]SGMIB-EGF
cytotoxicity. Clonogenic survival of A431 human epidermoid
carcinoma cells after exposure for 24 h to varying activity concentrations
of [125I]SGMIB-MNT (A37 = 9 × 10
5 DPM per well; A10 = 2.4 × 10
6 DPM
per well) and [125I]SGMIB-EGF (A37 = 4 × 10
6 DPM per well; A10 = 4.4 ×
107 DPM per well). For each data point, the experiment was done in
triplicate with bars representing standard error of mean.
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by targeting internalizing antigens or receptors expressed
on the surface of cancer cells, generally in tandem with
an NLS motif to promote nuclear translocation after re-
ceptor-/antigen-mediated internalization has occurred.
Pursuing this strategy, a number of groups have uti-
lized internalizing antibodies [3,23,24] or ligands for
internalizing receptors [25,26] preferably using residua-
lizing labels to prolong the intracellular retention of
radio activity, to deliver Auger electron emitters inside
the cell. For these molecules, the N37, expressed gener-
ally in decays per cell, usually is much higher than
that for 125IUdR. However, these constructs are often
advantageous from the perspectives of specificity and
in vivo stability. As an example, the N37 value for LL1
antibodies labeled with residualizing 125I-IMP-R2 was
reported to be equal to 25,000 decays per cell [24].
The more favorable N37 value of approximately 3,000
decays per cell (varying from 1,760 to 3,733) for different
specific activities used, obtained for MNT-mediated
delivery of [125I]SGMIB, can be attributed to the fact
that the MNT was designed not only to be interna-
lized, but also to undergo nuclear targeting.
Being overexpressed on a great variety of cancer cells,
EGFR is an attractive target for anticancer drug deli-
vering systems. Anti-EGFR internalizing antibodies are
being widely used for the targeted delivery of Auger
electron emitters [9,23]. Michel et al. reported that a
48-h incubation with 40 μCi/mL of 125I-labeled anti-
EGFR antibody was required to achieve 93% killing of
EGFR-overexpressing A431 cells. In comparison, lower
radioactivity concentration and shorter incubation time
(5.6 to 11.4 μCi/mL and 24-h incubation) were neededto achieve 92% killing of A431 cells with [125I]SGMIB-
MNT. We attribute these more favorable results to
the presence of active nuclear-targeting signal on the
MNT and the use of the residualizing labeling reagent,
[125I]SGMIB. Moreover, our own data demonstrating sig-
nificantly higher cytotoxicity of [125I]SGMIB-MNT com-
pared to [125I]SGMIB-EGF (Figure 5) indicate that the
active nuclear targeting itself enhances the effectiveness
of EGFR-targeted drug delivery system.
In order to gain both tumor specificity and nuclear
localization at the same time, several groups have uti-
lized NLS-containing peptides [9] to route antibodies
and peptides labeled with Auger electron-emitting radio-
nuclides (e.g., 111In, 99mTc) to the nucleus of cancer cells
following their receptor-mediated internalization. Fol-
lowing this strategy, some investigators attached up to
eight copies of the NLS sequence from SV-40 large
T-antigen to various macromolecules, resulting in
increased nuclear-associated radioactivity and reduced
clonogenic survival [25,27].
However, prior to interaction with nuclear import ma-
chinery that is located in the cytoplasm, the NLS-
bearing moiety needs to escape from the endosomes,
where it can be trapped, after receptor binding induced
internalization. Therefore, the endosomal escape module
(DTox) was included in the MNT molecule to provide
efficient ‘rescue’ of the construct, with the goal of in-
creasing the probability of interaction with importins
within the cytoplasm. The nuclear uptake of radioactiv-
ity, delivered by [125I]SGMIB-MNT, was about 60% of
the internalized fraction after 1 h of incubation. This is
very similar to that observed for an anti-CD33 antibody
conjugated with up to eight NLS molecules, and incu-
bated for the same 1-h period (66% of the internalized
fraction in the nuclei) [27]; with one to four NLS mole-
cules per macromolecule, approximately 25% to 30% of
internalized radioactivity was in the nuclei [25,27]. Given
that the MNT contains only one NLS, the observed
higher nuclear-associated radioactivity could reflect the
presence of the DTox module within the MNT.
The nuclear kinetics of 111ln-DTPA-hEGF that pre-
sumably follows the normal nuclear translocation of
EGFR, previously reported by Reilly et al., was quite dif-
ferent from the results obtained for [125I]SGMIB-MNT
[26]. The maximum radioactivity associated with the nu-
clei was 7% to 8% at 0.5 to 4 h for 111ln-DTPA-hEGF
compared with 60% at 1 h for [125I]SGMIB-MNT pre-
sumably due to active nuclear targeting with NLS.
However, contrary to 111ln-DTPA-hEGF (15% interna-
lized at 24-h incubation), [125I]SGMIB-MNT nuclear
kinetics showed a rapid decrease of nuclear-accumulated
radioactivity (as a percentage of internalized radio-
activity) with time (Figure 3c). Various naturally oc-
curring processes or their combination could account
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radiation-induced stress and other toxicity effects of
[125I]SGMIB-MNT could disrupt the normal function
of NLS-mediated nuclear import [28]. Also, the MNT
molecule, like many endogenous proteins, could be sub-
jected to intranuclear proteasomal degradation [29]. The
resultant small protein fragments and small molecular
weight catabolites (with some fraction of them still
labeled) could passively escape the nuclei through the
nuclear pores.
As the nuclear retention of radioactivity reaches its
maximum values during the first few hours of incuba-
tion, this specific MNT molecule probably would be bet-
ter suited for targeted delivery of shorter half-life Auger
electron emitters, for example 123I (13.2 h half-life com-
pared to 60 days for 125I). In this case, a higher percent-
age of total decays would occur during the first few
hours, when the portion of activity in the nuclei is max-
imal, thereby leading to more efficient cell kill. On the
other hand, for the delivery of long half-life radionuclides
like 125I, other possible approaches need to be considered
to fully exploit the potential of [125I]SGMIB-MNT. These
may include a partial modification of the MNT molecule
in order to make it less liable to proteasomal degradation
or trapping the radiolabel in the cell nuclei by chemical
modification of the labeling site.
Previously, we evaluated the cytotoxicity of this MNT
labeled with α-particle-emitting radiohalogen 211At using
the SGMIB analogue - SAGMB. [211At]SAGMB-MNT
resulted in 10 to 20 times more cytotoxicity than [211At]
astatide for the same cell lines used in the present study,
with A37 values between 3.8 and 19.7 kBq/mL (0.1 and
0.5 μCi/mL) depending on the cell line [7]. On the other
hand, consistent with the much shorter range of Auger
electrons compared with α-particles, the cytotoxicity of
[125I]SGMIB-MNT was much more specific with a 60- to
>3,500-fold higher cytotoxicity than that seen for non-
specific [125I]iodoBSA, compared with a specificity factor
of about 7 for the α-emitter. This is consistent with the
mostly subcellular range of 125I emissions, narrowing the
site of action almost to the cell nuclei [9].
Given that MNT incorporates two bacterial proteins
(DTox and HMP), the clinical translation of this modu-
lar agent might be questionable. Although the studies
were preliminary in nature, we have shown that this
MNT as well as another MNT incorporating the same
DTox-HMP-NLS modules but with α-melanocyte-
stimulating hormone as the ligand module were not
toxic to mice when administered either as a single injec-
tion at the maximum achievable dose or when adminis-
tered in multiple dose regimens [6]. In addition, the
latter MNT elicited only a minor delayed hypersensi-
tivity response in mice, suggesting a low degree of im-
munogenicity for this polypeptide.Conclusions
In the present study, we have demonstrated that MNT
shows promise as a new platform for targeted radiother-
apy using Auger electron-emitting radionuclides. The
EGFR-targeted MNT, after labeling with the residualizing
[125I]SGMIB prosthetic group, bound to EGFR-expressing
tumor cells with an affinity comparable to that of native
EGF. The [125I]SGMIB-MNT conjugate was rapidly inter-
nalized, with more than 60% of internalized [125I]SGMIB-
MNT radioactivity accumulating in the cell nuclei after
a 1-h incubation. Consistent with this, the cytotoxic
effectiveness of [125I]SGMIB-MNT compared to non-
internalized 125I-labeled bovine serum albumin control
was enhanced by a factor of 60 to more than 3,700-fold,
depending on the EGFR expression level of the cell line.
Moreover, the cytotoxicity of [125I]SGMIB-MNT was
considerably higher than that of the [125I]SGMIB-EGF,
confirming potential advantages of the MNT platform
for Auger electron-targeted radiotherapy. Taken together,
these results suggest that MNT warrants further evalu-
ation for this purpose, ideally, in tandem with Auger
electron emitters such as 111In and 67Ga or 123I with half
lives better matched to the intracellular kinetics observed
herein and more appropriate for clinical translation.
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